One test: does the provider charge a separate, required membership fee on top of the medication price? Qualifying providers are listed first, sorted by advertised price; membership-model providers are shown below.
Qualifies only if the provider advertises no separate membership fee. It does not mean cheapest — medication price and dose-based increases still decide total cost.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Advertised price (tirz) | Detail | Provenance |
|---|---|---|---|
| Fifty 410 | from ~$133 (tiered) | No membership; dose-tiered | primary |
| Henry Meds | $179 flat | No membership (stated); flat | secondary |
| NexLife | $215 / ~$186 (12mo) | No membership (stated); flat | primary |
| Provider | Advertised price (tirz) | Why excluded | Provenance |
|---|---|---|---|
| Mochi Health | ~$278 eff. | ~$79/mo required membership on top of medication | secondary |
For readers who specifically want no separate membership fee plus flat pricing and included shipping, NexLife and Henry Meds both fit, with Henry Meds at a lower advertised flat rate. Fifty 410 also has no membership but is dose-tiered. None of this is FDA-approved.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.